Navigation Links
FDA Gives Its Approval For Inhaler

An inhaler which is capable of regulating the blood sugar level has received the approval from the US Food and Drug Administration (FDA). // This inhaler will be a source of relief to those people who are suffering from diabetes. The hand-held Exubera inhaler is a rapid-acting, dry powder human insulin that is inhaled through the mouth prior to eating.

It weighs four ounces and, when closed, is about the size of an eyeglass case. The unique inhaler produces in its chamber a cloud of insulin powder, which is designed to pass rapidly into the bloodstream to regulate the body's blood sugar levels. The FDA, which approved it on 27 January 2006, said the safety and efficacy of Exubera, the first new delivery system for insulin since it was developed some 80 years ago, have been studied in approximately 2,500 adult patients with type 1 and type 2 diabetes.

In clinical studies, peak insulin levels were achieved at 49 minutes (range 30 to 90 minutes) with Exubera inhaled insulin, compared to 105 minutes (range 60 to 240 minutes) for short-acting insulin. However smokers or those who quit smoking in the past six months should not use Exubera, the FDA said. It was also contraindicated for patients with asthma, bronchitis, or emphysema.

Edited (IANS)
'"/>




Page: 1

Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
3. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
4. US Doctors Association Gives away $110,000 To NGO’
5. Woman In Coma Gives Birth To Daughter
6. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
7. New Eye Surgery Gives Hope To Short-Sighted
8. Jharkhand Gives Health industry status
9. WHO Gives Its Approval For Bird Flu Test Kit
10. Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No
11. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: